环氧合酶-2蛋白及前列腺素类物质与卵巢浆液性癌生物学行为的关系

目的　研究环氧合酶 2 (COX 2 )以及前列腺素类物质与卵巢浆液性肿瘤发生、发展的关系。方法　采用免疫印迹法及放射免疫法对 5 4例卵巢浆液性肿瘤组织 (其中良性卵巢浆液性肿瘤 11例 ,交界性良性卵巢浆液性肿瘤 10例 ,卵巢浆液性癌 3 3例 )和 10例正常卵巢组织进行COX 2蛋白、前列腺素 (PG)E2 、6 酮 前列腺素F1α(6 keto PGF1α)及血栓素 (TX)B2 水平检测。结果　 (1)COX 2蛋白表达 :卵巢浆液性癌组织的阳性表达率为 82 % (2 7/ 3 3 )、相对含量为 2 0 0 8± 3 5 3 ,交界性卵巢浆液性肿瘤分别为 90 % (9/ 10 )、2 0 61± 3 0 3 ,均明显高于良性卵巢浆液性肿瘤及正常卵巢 (阳性表达率均为0 ,相对含量分别为 15 0 4± 0 12及 15 3 3± 0 60 ) ,差异均有显著性 (P <0 0 5 ) ;卵巢浆液性癌患者不同临床分期 (Ⅰ～Ⅱ期与Ⅲ～Ⅳ期 )、病理分级及有无腹水、有无淋巴结转移间比较 ,差异均无显著性 (P>0 0 5 )。 (2 )前列腺素类物质PGE2 、6 keto PGF1α及TXB2 水平 :卵巢浆液性癌明显高于交界性、良性肿瘤和正常卵巢 (P <0 0 5 ) ,而后 3者间比较 ,差异无显著性 (P >0 0 5 ) ;卵巢浆液性癌患者不同临床分期 (Ⅰ～Ⅱ期与Ⅲ～Ⅳ期 )、病理分级及有无腹水、有无淋巴结转移间比较 ,差异均无显著性 (

Relationship between cyclooxygenase-2 protein expression,prostaglandins levels and biologic behavior in ovarian carcinoma tissue

OBJECTIVE: To study the relationship between cyclooxygenase-2 (COX-2) protein expression, prostaglandins levels assay and ovarian carcinoma biologic behavior in ovarian carcinoma tissue. METHODS: The levels of COX-2 protein, prostaglandin (PG) E(2), 6-keto-PGF(1 alpha) and thromboxane (TX) B(2) in 54 biopsy specimens from patients with ovarian serous tumor which included three groups: 33 samples of ovarian serous carcinomas; 10 samples of borderline ovarian serous tumors and 11 samples of benign ovarian serous tumors and 10 samples of normal ovarian tissues were detected by western blot analysis and radioimmunoassay to investigate their clinical significance. RESULTS: (1) The levels of COX-2 protein expression (82%, 27/33) and relative quantity (20.08 +/- 3.53) in ovarian serous tumor tissues were statistically higher than those in benign ovarian serous tumor tissues and in normal ovary tissues 0 and (15.04 +/- 0.12), 0 and (15.33 +/- 0.60), P < 0.05]. The level of COX-2 protein expression in borderline ovarian serous tumor tissues (90%, 9/10) and relative quantity (20.61 +/- 3.03) were statistically higher than those in benign ovarian serous tumor and normal ovary tissues (P < 0.05). The levels of COX-2 protein expression and relative quantity were found no significant differences in different clinical stages (I to II and III to IV), different histological grades, with or without ascites and lymphatic metastasis. (2) The levels of PGE(2), 6-keto-PGF(1 alpha) and TXB(2) in ovarian serous carcinoma tissues were statistically higher than in borderline ovarian serous tumor, benign ovarian serous tumor or normal ovarian tissues (P < 0.05). No significant differences of the levels were found among borderline tissues, benign tissues or normal ovarian tissues (P > 0.05). PGE(2), 6-keto-PGF(1 alpha) and TXB(2) were found no significant differences in different clinical stages (I to II and III to IV), different histological grades, with or without ascites and lymphatic metastasis. (3) COX-2 expression was correlated with PGE(2), 6-keto-PGF(1 alpha) and TXB(2) (P < 0.01). CONCLUSIONS: (1) Our data suggest that COX-2 overexpression leads to increased PGE(2), 6-keto-PGF(1 alpha) and TXB(2) biosynthesis, which may be mechanisms underlying the contribution of COX-2 to the development of ovarian serous carcinoma. (2) PGE(2), 6-keto-PGF(1 alpha) and TXB(2) may be helpful parameters of diagnosis and differentiate diagnosis in ovarian serous carcinoma.